Amoéba, the French industrial greentech firm developing microbiological crop protection solutions, is accelerating the path to market for its flagship biocontrol product AXPERA after highly positive results from vineyard trials across Europe. The company announced that it will present these findings to the agricultural press on October 28, 2025, underscoring its confidence in securing regulatory approvals aligned with a planned 2026 commercial rollout.

The breakthrough comes on the back of a 120-day emergency marketing authorization granted by French authorities earlier this year to combat widespread mildew outbreaks. AXPERA was tested extensively across major winegrowing regions—Bordeaux, Burgundy, Provence, Champagne and Beaujolais—where mildew and powdery mildew posed significant challenges. Initial grower feedback has been strikingly favorable. Many reported that AXPERA not only matched but in some cases outperformed traditional copper-based treatments, while allowing substantial reductions in copper use.

Winegrowers such as Victor Sornin in Beaujolais described cutting copper inputs to just 1 kg per hectare while achieving superior mildew protection compared to standard regimes. Similarly, Anne Silberzahn of Côtes de Provence highlighted that she halved her copper use without compromising efficiency, reinforcing her belief that copper dependency could be eliminated altogether. Such testimonials are particularly timely given the July 2025 regulatory decision by ANSES, France’s health authority, to withdraw over half of the copper-based fungicides available against mildew—a development that has shaken the sector and heightened demand for credible alternatives.

As AXPERA earns trust in the field, Amoéba is also advancing the regulatory process across key international markets in partnership with biocontrol major Koppert. In the United States, while a budget squeeze in Washington has delayed the Environmental Protection Agency’s decision on AXPERA until early 2026, California has moved faster than expected, with toxicological assessments completed and potential authorization anticipated the same year.

In Brazil, ANVISA has already validated AXPERA’s non-toxicological classification, while the Ministry of the Environment (IBAMA) is conducting further studies on soil microorganism impact. A final decision by the Ministry of Agriculture could come by mid-2026. In Europe, the authorisation procedure has been initiated in nine member states, with France acting as rapporteur. ANSES has confirmed the admissibility of Amoéba’s dossier, with conclusions expected by early 2026, keeping the company’s timeline intact.

For the European wine industry, AXPERA represents more than a product launch—it marks a potential turning point in sustainable viticulture. With regulators tightening restrictions on copper and climate pressures intensifying fungal risks, the solution offers growers a scientifically validated, natural, and environmentally safe option. For Amoéba, the successful deployment of AXPERA positions the company at the forefront of a rapidly expanding biocontrol market, where grower confidence and regulatory clarity are set to drive adoption.

By marrying science-based innovation with favorable regulatory momentum, Amoéba is setting the stage for AXPERA to become a benchmark in sustainable crop protection—a solution that could redefine how the world’s vineyards defend themselves against disease while meeting the twin imperatives of environmental stewardship and profitability.